Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Market Cap	4.07B
Revenue (ttm)	512.85M
Net Income (ttm)	145.78M
Shares Out	104.52M
EPS (ttm)	1.37
PE Ratio	28.40
Forward PE	n/a
Dividend	1.00 (2.57%)
Ex-Dividend Date	Jan 10, 2025

Volume	1,052,857
Average Volume	917,723
Open	39.30
Previous Close	39.30
Day's Range	38.53 - 39.78
52-Week Range	23.38 - 41.36
Beta	0.48
RSI	52.83
Earnings Date	Apr 26, 2025

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. The company was founded in 2008 and is based in Hangzhou, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 629
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688767

Financial Performance

In 2024, Hangzhou Biotest Biotech's revenue was 560.59 million, an increase of 26.80% compared to the previous year's 442.11 million. Earnings were 176.68 million, an increase of 65.74%.